By: IPP Bureau
Last updated : October 10, 2025 5:37 pm
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
Integris Medtech, the second largest Indian headquartered diversified medical technology platform in terms of operating revenue for FY25, has filed its Draft Red Herring Prospectus (DRHP) with market regulator Securities and Exchange Board of India (SEBI).
The IPO comprises of a fresh issue of equity shares of face value Rs. 1 each aggregating up to Rs. 925 crores and an offer for sale of up to 21,674,531 equity shares of face value Rs. 1. The offer for sale by promoter selling shareholders comprises of up to 15,174,251 equity shares by Evercure Holdings Pte. Ltd., up to 3,250,140 equity shares by Gurmit Singh Chugh and up to 3,250,140 equity shares by Punita Sharma.
In consultation with the BRLMs, the company may consider a pre IPO placement of Rs. 185 crores prior to the filing of the RHP with ROC.
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans, along with any interest and prepayment charges amounting to Rs 696.39 crores taken by its wholly owned subsidiaries as well as by its step-down subsidiaries. A portion of the funds will also be used for general corporate purposes.
The company has grown at the back of growth capital it received from Everstone Capital in 2019 that resulted in strategic acquisitions in Europe and in the laboratory sector, securing proprietary technologies for complex coronary interventions and extending its reach to scientific and clinical laboratories and as on date stands to be the world’s only company to have two drug eluting stent platforms such as VIVO ISAR and Yukon Choice.
Its tech led expansion is illustrated by its acquisition of Translumina GMBH and Blue Medical Devices in 2004 similarly for geographic and category diversification it did bolt on acquisitions of Lamed Gmbh and for leadership consolidation and market access it acquired Research Instruments, Biofrontier, Analisa Resources and Sciences Resources.
In 2025 it acquired 100% shares of Everlife Holdings Pte Ltd. It has completed 17 acquisitions across cardiovascular and laboratory solutions. Their build, partner and acquire strategy has been deliberate to fuel growth, expand reach, address technology gaps and strengthen innovation and service delivery.
It is the country’s second largest coronary stent manufacturer with an estimated 22.0% market share in drug-eluting stents and is also the largest scientific laboratory solutions company in Southeast Asia.
It is one of only two Indian companies producing all three classes of medical devices, with over 2,500 SKUs manufactured in-house across facilities in Dehradun, India, Hechingen in Germany, and Helmond in the Netherlands.
As of June 30, 2025, Integris had partnered with over 2,000 hospitals and Cath labs and worked with 9,500 laboratories globally, offering 22,000 SKUs across more than 200 brands. Its lab solutions segment represents over 200 global manufacturers, including Euroimmun, Biorad, bioMérieux, and MGI, serving clinical and scientific labs across India and Southeast Asia.
Over 60% of its revenues comes from international markets due to its global portfolio across the cardiovascular, scientific lab solutions and clinical diagnostic verticals.
ICICI Securities Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited And IIFL Capital Services Limited (formerly known as IIFL Securities Limited) are the bankers to the issue.